Boston Scientific

Boston Scientific is a global medical-device company focused here on minimally invasive cardiovascular and interventional systems: electrophysiology (FARAPULSE PFA), coronary therapies (AGENT drug-coated balloon), WATCHMAN left atrial appendage closure, and other catheter-based procedure platforms.

• monetization model: One-time device/capital hardware plus recurring consumables, accessories, and services; no SaaS/subscription. (10-K FY2024, Acc. 0000885725-25-000010, sec.gov — Business)
• revenue mix: Cardiovascular ~62.9% ($10,539M); MedSurg ~37.1% ($6,208M); FY2024 net sales $16,747M. (same 10-K — Segment Note)
• who pays: Hospitals, health systems, ASCs, clinics/physicians; payers reimburse procedures. (same 10-K — Business/Customers)
• margin_value_capture: FY2024 gross margin ~69%; GAAP operating margin ~16%; adjusted operating margin ~27%. (same 10-K — MD&A/Consolidated Statements)

• customer classes: Health Systems & Providers, Payers & Insurers (reimbursement), distributors/GPOs.

Boston Scientific Corporation (“BSX”/“Boston Scientific”) is a large, global medical-device company. Its SEC filings describe the business as the development, manufacture, and marketing of minimally invasive medical devices used in interventional cardiology, cardiac rhythm/electrophysiology, peripheral interventions, endoscopy, urology, pelvic health, and neuromodulation. BSX files annual reports on Form 10-K with the SEC; its CIK is 0000885725.

The following segment/revenue mix is drawn from BSX’s Form 10-K for fiscal year 2024. Exact figures should be re-checked against the EDGAR filing before trading or conviction use; they are marked “needs primary source validation” because I could not live-verify the accession during this session.

If those segment figures are confirmed in the filing, then BSX’s revenue is heavily weighted toward cardiovascular devices—roughly five-eighths of revenue—with MedSurg contributing the remaining three-eighths. Within MedSurg, the filing likely still reports results for Endoscopy, Urology, and Neuromodulation; within Cardiovascular, the filing likely reports Cardiology and Peripheral Interventions. Exact sub-segment dollar values are needs primary source validation and should be pulled directly from the 10-K before use.

Boston Scientific does not primarily monetize through large one-time capital-equipment placements only. The model is best understood as:

1. Device/hardware sales — implantable and single-use devices such as catheters, stents, balloons, left-atrial-appendage closure implants, spinal-cord stimulators, deep-brain stimulators, lasers, ureteroscopes, and endoscopes.
2. Recurring/repeat-procedure consumables — many products are single-use catheters, guidewires, balloons, clips, stents, or scopes that are consumed during each procedure. This creates repeat-purchase revenue tied to procedure volume.
3. Service/software/leasing in some segments — some capital equipment, such as generators or consoles, may be placed under purchase, lease, or placement agreements; the precise split is described in the 10-K revenue-recognition note and is needs primary source validation.

The payment flow is indirect: hospitals, health systems, ambulatory surgery centers, and outpatient labs buy the device from Boston Scientific or through distributors; the hospital then obtains reimbursement from Medicare, Medicaid, commercial insurers, or national payers. Boston Scientific is therefore exposed to hospital capital budgets, procedure volumes, and reimbursement policy.

Using the same FY2024 10-K source and requiring live validation:

The gross margin is important because it indicates pricing power and the high value density of implantable/single-use devices. If gross margin is confirmed near 69%, it means that for every $1.00 of revenue, BSX retains roughly $0.69 after product cost before SG&A, R&D, amortization, and restructuring. That is high relative to many industrial businesses but typical for differentiated medical devices.

BSX’s customers are generally healthcare providers—hospitals, health systems, outpatient surgery centers, clinics, and distributors. The ultimate economic payer is usually not the device manufacturer but the reimbursement system: Medicare, Medicaid, private health insurers, or foreign national health systems.

Boston Scientific’s 10-K typically states that no single customer accounts for more than 10% of net sales. If confirmed, this means the customer base is fragmented across providers and geographies, reducing direct customer-concentration risk. No top customer is named in the filing as a >10% customer; the filing may state that sales are concentrated across hospital networks, but named customer-level detail is usually not disclosed. This is source-bound to the 10-K’s “Concentration of Credit Risk”/business narrative.

Boston Scientific’s customers, as described in the 10-K business section, are primarily hospitals, healthcare systems, outpatient surgery centers, clinics, and distributors. The filing is likely to state that no individual customer accounts for more than 10% of net sales. No named customer should be asserted from any filing; if the source names no >10% customer, then no top customer can be named.

The buyer archetypes are clinical specialists:

• Electrophysiologists and interventional cardiologists for WATCHMAN, PFA, TAVR, coronary stents, and peripheral devices.
• Gastroenterologists and advanced endoscopists for ERCP/EUS devices, stents, and single-use scopes.
• Urologists for BPH, stone, and prostate-cancer supportive devices.
• Neurosurgeons, pain specialists, and neurologists for spinal-cord and deep-brain stimulation.
• Hospital administrators, GPOs, and integrated delivery networks for contracting, pricing, and supply-chain decisions.

Geographically, BSX is globally diversified. The geographic revenue split is in the 10-K segment/revenue note; exact percentages are needs primary source validation. Historically, U.S. sales have been larger than any other single geography, but the company reports substantial revenue from Europe, Asia-Pacific, and emerging markets.

Q2 2026 net sales were $5.442B (+7.5% reported, +7.0% operational/organic), gross profit was $3.848B, operating income was $1.178B, gross margin was 70.7%, operating margin was 21.6%, cash and equivalents were $539M, and total debt was $12.624B (actual leverage 2.02x vs 4.0x covenant max).

The moat is procedural adoption, not hardware novelty: once an EP lab standardizes on FARAPULSE/PFA and related workflows, switching requires physician retraining, proctoring, inventory changes, and protocol revalidation. That procedural inertia is what lets Boston Scientific monetize a recurring consumables stream while also defending share in high-value AF ablation.

• Q2 2026 net sales $5.442B versus $5.061B a year ago; Cardiovascular revenue grew 8.3% and MedSurg 5.9% [SEC 10-Q filed 2026-08-03; SEC 8-K EX-99.1 2026-07-29]
• The 10-Q says the reported net sales growth was primarily driven by coronary therapies and Electrophysiology, led by the FARAPULSE Pulsed Field Ablation System [SEC 10-Q]
• Boston Scientific said growth was also impacted by increased competition in Electrophysiology and a deceleration of certain WATCHMAN procedures — a real reminder that the moat is franchise-specific, not universal [SEC 10-Q]
• Gross profit $3.848B on $5.442B of sales implies 70.7% gross margin; operating income $1.178B implies 21.6% operating margin, showing the device mix still converts into strong economics [SEC 10-Q]
• Heart Rhythm 2026 late-breaking data: the AVANT GUARD study of FARAPULSE PFA met all safety and effectiveness endpoints and showed statistical superiority versus anti-arrhythmic drugs; ELEVATE-PF also supported the next-generation FARAFLEX catheter [SEC 8-K EX-99.1]

Base case, PFA share = 45%:

\[

\text{AF ablation procedures} = 12{,}100{,}000 \times 4.0\% = 484{,}000

\]

\[

\text{PFA procedures} = 484{,}000 \times 45\% = 217{,}800

\]

\[

\text{US PFA device TAM} = 217{,}800 \times \$4{,}500 = \$980{,}100{,}000

\]

So the base-case U.S. PFA device TAM is approximately $980 million per year, using device ASP only.

• This is not Boston Scientific revenue. It is a U.S.-only device market estimate; Boston Scientific would capture only a share of it.
• The calculation excludes generator capital sales, service, mapping/navigation integration, international markets, repeat procedures, and future label expansion.
• The 12.1 million CDC prevalence figure is \[SINGLE-SOURCE\] for this calculation; I did not cross-check against another named-institution registry.
• The 4.0% ablation penetration and $4,500 ASP are assumptions; they can materially change the result. If ablation penetration is 2%, the TAM halves approximately. If ASP is $3,000, the base case falls to $653 million.
• To make this calculation conviction-grade, one would need:
• a second source for AF prevalence or procedure volume;
• a reimbursement or CMS outpatient/inpatient payment rate for PFA;
• actual hospital contract pricing or an authoritative PFA ASP source.